Nycomed US announces executive changes

MELVILLE, N.Y. — In line with its new position as a stand-alone corporation, the former U.S. subsidiary of a Swiss drug maker has appointed a new leader.

Nycomed US announced that Brian Markison, former chairman and CEO of King Pharmaceuticals, will lead the company as president, CEO and a member of the board. The company also appointed Jeff Bailey as COO and John Golubieski as CFO. Both Bailey and Golubieski also held executive roles at King.

Nycomed US was the U.S. subsidiary of Nycomed, prior to the pharmaceutical company's acquisition by Takeda. Nycomed US will continue to be owned by Nycomed's current private equity owners, but will operate as an independent entity.

"I am delighted, along with Jeff and John, to join the team at Nycomed US. This is an exciting time for the company because we have the opportunity to grow aggressively and forge our future as an independent entity," Markison said. "Jeff and John are great additions to an already strong and focused management team and I am confident we can leverage the company's financial strength and unique platform within the dermatology market to drive further growth in our business."